(NASDAQ: QNCX) Quince Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 84.56%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Quince Therapeutics's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast QNCX's revenue for 2027 to be $1,860,108,825, with the lowest QNCX revenue forecast at $972,219,744, and the highest QNCX revenue forecast at $2,747,997,906. On average, 2 Wall Street analysts forecast QNCX's revenue for 2028 to be $4,126,025,393, with the lowest QNCX revenue forecast at $2,750,146,458, and the highest QNCX revenue forecast at $5,501,904,329.
In 2029, QNCX is forecast to generate $6,864,354,815 in revenue, with the lowest revenue forecast at $5,468,064,636 and the highest revenue forecast at $8,260,644,994.